DDX3X and cancer: Avenanthramide A, the effective ingredient in avenanthramides, exhibited anti-cancer activities in CRC cells with DDX3X highly expressed via directly binding to ATP-binding domain of oncogenic protein DDX3X to block the ATPase activity of DDX3X and induce its degradation (140).